NovaBridge Biosciences (NBP) Other Non-Current Liabilities (2018 - 2025)

NovaBridge Biosciences (NBP) has reported Other Non-Current Liabilities for 6 consecutive years, with $511000.0 the latest figure, recorded in Q4 2025.

• Quarterly Other Non-Current Liabilities changed N/A year-over-year to $511000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $511000.0 (changed N/A YoY) and the FY2025 annual result came in at $511000.0, changed N/A from the prior year.
• Other Non-Current Liabilities eased to $511000.0 in Q4 2025 per NBP's latest filing, from $9.7 million in the prior quarter.
• Over the last five years, Other Non-Current Liabilities for NBP reached as high as $2.3 billion in Q4 2021 and fell as low as $511000.0 in Q4 2025.
• A 4-year average of $336.9 million and a median of $2.4 million in 2022 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2021 — Other Non-Current Liabilities soared 172378.56% — and 2022, when it tumbled 99.9%.
• Year by year, Other Non-Current Liabilities stood at $2.3 billion in 2021, then tumbled by 99.9% to $2.4 million in 2022, then surged by 305.67% to $9.7 million in 2023, then plunged by 94.72% to $511000.0 in 2025.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $511000.0, $9.7 million, and $6.8 million for Q4 2025, Q4 2023, and Q2 2023 respectively.